Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
-
ORGANIZATION Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
-
REGULATORY Industry Won’t Grow If Pricing Premium Ended, Pharma Leaders Tell Govt
April 14, 2015
-
REGULATORY JPA’s Abe Says Link between Pricing Premium and New Drug Development Blurry
April 13, 2015
-
REGULATORY PAFSC’s Second Committee to Review PegIntron, Talion on April 24
April 13, 2015
-
BUSINESS Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
-
BUSINESS Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
-
BUSINESS Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
-
BUSINESS Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
-
ORGANIZATION JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
-
BUSINESS Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
-
ACADEMIA Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
-
BUSINESS Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
-
BUSINESS Lupin Group’s Kyowa Sees Japan-India Collaboration as Key to Survival: Pres.
April 1, 2015
-
ACADEMIA CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
-
BUSINESS Fujifilm to Buy US iPS Cell Manufacturer Cellular Dynamics
March 31, 2015
-
REGULATORY Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
-
BUSINESS Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
-
REGULATORY Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
-
BUSINESS Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…